Juliette Han, Cambrian Bio | theCUBE + NYSE Wired: MedTech Unplugged
Show Notes
This episode of theCUBE Research's MedTech Unplugged features Juliette Han, CFO and COO of Cambrian Bio, discussing innovative MedTech strategies aimed at extending health span. Recorded in collaboration with NYSE Wired, the conversation delves into Cambrian Bio's focus on translational research that targets metabolic health, the mechanistic target of rapamycin (mTOR), and clinically-backed dermatological products. Han emphasizes the importance of prioritizing health span over mere longevity and highlights the company's diverse programs addressing obesity, diabetes, and dermatology. The discussion also covers the role of artificial intelligence in drug discovery and the complex regulatory landscape that biotech startups must navigate. Listeners will gain insights into the challenges and opportunities facing the biotech industry as it strives to innovate in drug development and patient care.
Key Topics Covered:- Cambrian Bio's approach to improving health span through focused research and development.
- Discussion on the significance of metabolic health and the implications for obesity and diabetes.
- Insight into a new science-backed skin product launching this spring.
- The role of AI in drug discovery and its limitations compared to human clinical testing.
- Investor engagement strategies and the impact of market dynamics on biotech development.
- Regulatory considerations and interactions with the FDA in the drug approval process.
- Challenges in communicating the drug development process to potential investors and the public.
- Future directions for Cambrian Bio, including ongoing trials and new therapeutic programs.